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1. Introduction 
Resistance to thyrotropin (RTSH) is a condition in which thyroid cells show reduced 
sensitivity to TSH. This condition is characterized by elevated serum TSH concentration, a 
normal or hypoplastic thyroid gland and normal to very low levels of thyroid hormones. 
Loss-of-function mutations in the TSH receptor gene (TSHR) lead to RTSH syndrome, 
presenting with either congenital hypothyroidism (CH) or subclinical hypothyroidism 
(Beck-Peccoz et al., 2006; Refetoff, 2003). 
CH occurs in about 1 in 3500 live births. Thyroid dysgenesis is responsible for 75% of these 
cases, dyshormonogenesis for 15%, central hypothyroidism for 5%, and 5% are due to other 
causes (Grüters et al., 2003; Kratzsch & Pulzer, 2008). Most cases of CH due to thyroid 
dysgenesis occur sporadically, but 2% of the patients are familial (Castanet et al., 2000, 2001). 
Dyshormonogenesis is commonly recessively inherited (Park & Chatterjee, 2005). Genes 
associated with thyroid gland dysgenesis include TITF1, TITF2 and PAX8 (De Felice & Di 
Lauro, 2004; Gillam & Kopp, 2001(a); Park & Chatterjee, 2005). Thyroid dyshormonogenesis 
is caused by genes that are involved in thyroid hormone synthesis including 
thyroperoxidase (TPO), thyroglobulin (TG), sodium iodide symporter (NIS), pendrin (PDS), 
dual oxidase 2 (DUOX2) and its maturation factor (DUOXA2), and dehalogenase (DEHAL1) 
(Gillam & Kopp, 2001(b); Grasberger & Refetoff, 2010). Loss-of-function mutations in TSHR 
lead to a spectrum of phenotypes, depending on the mutation's location and severity 
(Biebermann et al., 2010; De Felice & Di Lauro, 2004). The first report in 1968 of RTSH was of 
an 8-year-old boy with cretinism in whom the thyroid gland was small in a 99mTC scan and 
radioiodine uptake was normal (Stanbury et al., 1968). It was only in 1995 that the cause for 
RTSH syndrome in that case was shown to be a mutation in TSHR (Sunthornthepvarakul et 
al., 1995). Since the first report of CH caused by a TSHR mutation, several cases of loss-of-
function mutations of TSHR have been reported: most are missense mutations, but deletions 
and insertions have been identified as well (see http: www.hgmd.cf.ac.uk/ac/ 
gene.php?gene=TSHR and OMIM#275200) (Abramowicz et al., 1997; Alberti et al., 2002; 
Biebermann et al., 1997, 2010; Bretones et al., 2001;  Camilot et al., 2005; Cangul et al., 2010; 
Clifton-Bligh et al., 1997; De Marco et al., 2009; de Roux et al., 1996; Fricke-Otto et al., 2005; 
Gagne et al., 1998; Grasberger et al., 2007; Jeziorowska et al., 2006; Jordan et al., 2003; Kanda 
et al., 2006; Nagashima et al., 2001; Narumi et al., 2009; Narumi et al., 2011; Park et al., 2004; 
www.intechopen.com
 Hypothyroidism – Influences and Treatments 
 
296 
Richter-Unruh et al., 2004; Rubio et al., 2008; Russo et al., 2000;  Sriphrapradang et al., 2011; 
Sunthornthepvarakul et al., 1995; Sura-Trueba et al.,2009; Tenenbaum-Rakover et al., 2009; 
Tiosano et al., 1999; Tonacchera et al., 2000, 2001, 2004; Tsunekawa et al., 2006; Wonerow et 
al., 2001) (Table 1, Fig 1). 
2. TSHR: Structure and function 
TSH controls thyroid function upon its interaction with the G-protein-coupled TSHR. The 
family of G-protein-coupled receptors (GPCRs) shares seven transmembrane segments 
connected by three extracellular and three intracellular loops (ECL and ICL, respectively). 
Together with the receptors for glycoprotein hormones LH/HCG and FSH, TSHR has a long 
N-terminal domain that is involved in recognition and binding of the ligand. The TSHR 
gene located on chromosome 14q31 was cloned in 1989 (Libert et al., 1989). It encodes a 
protein with a large N-terminal ligand-binding extracellular domain, a hepta-helical 
transmembrane domain and an intracellular domain. The extracellular domain is encoded 
by the first nine exons and part of exon 10, whereas the transmembrane and intracellular 
domains are encoded entirely by exon 10. The protein consists of 744 amino acids and the N-
terminal ectodomain consists of 398 amino acids composed of eight leucine-rich repeat 
motifs (Szkudlinski et al., 2002; Van Durme et al., 2006). Similar to other GPCRs, TSHR 
shares a common mode of intracellular signaling, stimulating the exchange of GDP for GTP 
on the Gα subunit (Gsα) and phosphoinositol (IP) turnover through Gq coupling. TSH 
binding to TSHR on the basolateral membrane of the thyroid follicular cells leads to 
stimulation of secondary-messenger pathways involving these two main pathways: 
Gs/cAMP, which mediates hormone secretion, thyroid cell growth and differentiation and 
iodide uptake, and IP/Ca+2, which regulates thyroid hormone synthesis by stimulating 
iodide organification (Dumont et al., 1992; Vassart & Dumont, 1992; Wonerow et al., 2001). 
Mutations in TSHR result in either gain or loss of receptor function.  
3. Gain-of-function mutations in TSHR 
Germline gain-of-function mutations result in non-autoimmune hyperthyroidism, whereas 
somatic mutations that constitutively activate TSHR result in toxic thyroid nodules. 
Hyperthyroidism caused by germline mutations in TSHR exhibits autosomal dominant 
inheritance. The mutations are located mainly in exon 10, which encodes the transmembrane 
region and intracellular tail that constitutively activate TSHR. The phenotype of these 
patients is characterized by hyperthyroidism with the presence of goiter but the absence of 
ophtolmopathy, and a lack of thyroid autoantibodies as well as of lymphocytic infiltration in 
thyroid histology (Van Sande et al., 1995). The clinical spectrum of phenotypes is variable 
and onset can occur anywhere from birth to adulthood. The presence of either congenital or 
adulthood-onset hyperthyroidism, multinodular goiter (MNG) and follicular carcinoma has 
been reported in the same family (Karges et al., 2005). To date, more then 55 germline gain-
of-function mutations have been reported, about 14 of them sporadic and the others with 
familial occurrence (http: www.hgmd.cf.ac.uk/ac/gene.php?gene=TSHR) (Akcurin et al., 
2008; Davies et al., 2005; Farid et al., 2000; Führer et al., 1997(b);  Holzapfel et al., 1997; 
Karges et al., 2005; Khoo et al., 1999; Tonacchera et al., 1996; Van Sande et al., 1995). 
Hyperthyroidism in affected individuals is often resistant to the conventional treatment 
used in Graves’ disease, and either radiotherapy or total thyroidectomy is required. 
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Autonomous benign and malignant toxic thyroid nodules have been shown to result from a 
variety of somatic mutations leading to constitutive activation of TSHR and affecting cell 
proliferation and cell function. Somatic TSHR mutations commonly occur in the 
transmembrane and ECL domains, but hot spots are the sixth transmembrane domain and 
the third ICL where the receptor interacts with G-proteins. Toxic adenoma due to TSHR-
activating mutations may occur in infancy (Kohn et al., 2009) or even in utero (Kopp et al., 
1997) (OMIM#2603372) (Davies et al., 2005; Führer et al., 1997(a); Kohn et al., 2009). To date, 
about 25 different somatic TSHR-activating mutations have been reported manifesting with 
toxic adenoma, MNG and toxic thyroid carcinoma. 
4. Loss-of-function mutations in TSHR 
About 50 different loss-of-function mutations have been described in TSHR (Table 1). 
Affected individuals are either homozygous, compound heterozygous or heterozygous. The 
degree of insensitivity to TSH depends on the type and location of the TSHR mutation; more 
severe loss of TSHR function manifests as CH, whereas mild mutations present with 
euthyroid hyperthyrotropinemia or subclinical hypothyroidism. When both alleles carry 
mutated receptors with complete lack of function, the result is severe hypothyroidism, 
commonly presenting at birth, whereas carriers of a mutation on one allele present with 
compensated hyperthyrotropinemia. The thyroid gland is hypoplastic or invisible in a 99mTC 
scan; however, in ultasonographic imaging, the gland is shown to be in a normal position 
and commonly of small size. TSHR mutations are distributed all along the receptor. 
Mutations located in the binding domain result in reduced binding capacity or decreased 
membrane expression of the receptor. The third ECL and the seventh intracellular domain of 
TSHR are hot spots for gain-of-function mutations, but some inactivating mutations have 
been identified in this domain as well (Alberti et al., 2002; Grasberger et al., 2007; Tiosano et 
al., 1999) (Fig. 1).  
4.1 Prevalence of loss-of-function mutations 
The exact prevalence of inactivating TSHR mutations is not known. A prevalence of 4.3% 
biallelic TSHR mutations was found among 134 Japanese infants with CH (Narumi et al., 
2009). Among 38 children with non-autoimmune subclinical hypothyroidism, 11 (29%) were 
carriers of TSHR mutations (Nicoletti et al., 2009). A prevalence of 12% TSHR mutations was 
shown in 42 subjects with non-autoimmune isolated hyperthyrotropinemia in Italy; all were 
with familial occurrence (Tonacchera et al., 2004). Camilot et al. (2005) identified 13 patients 
with heterozygous mutations (11%) out of 116 pediatric patients with asymptomatic 
euthyroid hyperthyrotropinemia. A rate of 0.6% for carriers of W546X-mutated TSHR was 
identified in Welsh euthyroid individuals (Jordan et al., 2003). We found up to 2.4% carriers 
of two known mutations in a highly consanguineous population in the northern region of 
Israel (Tenebaum-Rakover et al., 2009). Moreover, the coexistence of two different novel 
mutations of TSHR in each of two separate clans has been shown (Sriphrapradang et al., 
2011). In view of these data, it may be speculated that the occurrence of inactivating TSHR 
mutations in certain populations is not so rare, and therefore screening for TSHR mutations 
is indicated in cases with non-autoimmune subclinical hypothyroidism in those 
populations.  
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Fig. 1. Scheme of TSHR with known loss-of–function mutations 
4.2 Clinical characteristics  
Loss-of-function mutations manifest with a variable clinical spectrum of phenotypes. Severe 
uncompensated RTSH presents with CH, partially compensated RTSH manifests with 
subclinical hypothyroidism, and fully compensated RTSH presents with euthyroid 
hyperthyrotropinemia or even normal thyroid function. The diagnosis of TSHR defect is 
based on the absence of thyroid antibodies, a lack of goiter, measurable serum 
thyroglobulin, and familial occurrence of hyperthyrotropinemia or hypothyroidism. CH is 
commonly detected by TSH-based neonatal screening but may missed by total T4 (TT4)-
based screening since, in many cases, TT4 levels are within the normal range at birth (Table 
1). The degree of CH is variable and depends on the genotype. Severe forms manifest as 
overt CH (Bretones et al., 2001; Gagne et al., 1998; Jeziorowska et al., 2006; Park et al., 2004; 
Tonacchera et al., 2000), moderate forms as hypothyroidism identified by neonatal screening 
without clinical symptoms of hypothyroidism (Abramowicz et al., 1997; Jordan et al., 2003), 
and mild forms present with hyperthyrotropinemia and normal thyroid hormones (de Roux 
et al., 1996; Nagashima et al., 2001; Narumi et al., 2009; Tenenbaum-Rakover et al., 2009). 
Gagne et al. (1998) described a case of CH with persistent neonatal jaundice, myxedematous 
facies, large fontanelle and absence of ossification centers of the knee on x-rays, indicating 
severe prenatal deficiency of thyroid hormone. Most of the described cases of CH are 
detected by neonatal screening with elevated TSH and normal TT4 levels, but without any 
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clinical symptoms or signs of hypothyroidism (de Roux et al., 1996; Tenenbaum-Rakover et 
al., 2009). Nevertheless, L-T4 therapy is initiated in most cases to prevent future 
consequences of untreated CH. At the age of 2 to 3 years, when L-T4 is withdrawn, thyroid 
hormones remain low in the severe mutations (Abramowicz et al., 1997; Biebermann et al., 
1997; Tonacchera et al., 2000); however in milder mutations, despite extremely elevated 
TSH, thyroid hormone levels are normal, indicating compensated hypothyroidism (Clifton-
Bligh et al., 1997; Tenenbaum-Rakover et al., 2009). 99mTC scan commonly reveals a normal 
or hypoplastic gland but in some cases, an absence of thyroid gland has been demonstrated, 
suggesting thyroid agenesis (Table 1). The presence of detectable thyroglobulin as well as 
the demonstration of a thyroid gland in the normal position in ultrasonographic imaging 
exclude thyroid agenesis and indicate a diagnosis of RTSH. In a few reports, an enlarged 
thyroid gland has been described (de Roux et al., 1996; Grasberger et al., 2007). Inactivating 
TSHR mutations at older ages present with either subclinical hypothyroidism or euthyroid 
hyperthyrotropinemia without thyroid autoantibodies. The affected patients are commonly 
identified by routine laboratory tests and are asymptomatic. Most of the described cases are 
heterozygous for TSHR mutations, but biallelic mutations have been reported as well 
(Kanda et al., 2006; Russo et al., 2000;  Sriphrapradang et al., 2011; Tenenbaum-Rakover et 
al., 2009; Tonacchera et al., 2001, 2007).  
4.3 Mechanism of loss-of-function mutations  
The mechanism leading to loss-of-function of TSHR includes abnormal binding affinity, 
abnormal receptor synthesis, accelerated degradation, defective receptor targeting to the cell 
membrane and abnormal signal transduction (Tao, 2006). Mutations may exert their activity 
by causing protein misfolding, misassembly or aberrant oligomerization. Loss-of-function 
mutations are located all along the TSHR (Biebermann et al., 2010) (Fig 1). The function of 
TSHR is assessed in vitro by cAMP response, IP accumulation, TSH binding and cell-surface 
expression of the mutated receptor. The analysis is performed with COS-7 cells transfected 
with the mutant receptor. Each mutation has a different effect on binding capacity, 
membrane expression and cAMP and IP accumulation, depending on its type and location 
along the TSHR. In in-vitro studies, it has been shown that TSHR mutations differ in their 
effect on the Gs and Gq pathways, which may lead to more severe loss of one pathway 
compared to the other (Claus et al., 2005). The third ECL represents an important domain for 
intermolecular TSHR signal transduction and single amino acids play different roles in 
receptor folding and cAMP and IP signaling (Claus et al., 2005). We identified a biallelic 
L653V mutation located in the third ECL in three sisters presenting with marked 
hyperthyrotropinemia and increased thyroid radioiodine uptake (Grasberger et al., 2007). 
Normal ligand binding, slightly reduced cell expression and mildly reduced basal and 
stimulated cAMP accumulation with markedly reduced IP formation were found in in-vitro 
studies using transfected COS-7 cells. These in-vitro findings explained the phenotype of the 
affected subjects manifesting compensated hyperthyrotropinemia concomitant with 
increased iodide uptake, and this was the first report to provide in-vivo evidence of the 
important role of the IP/Ca+2 pathway in the regulation of thyroid hormone synthesis. 
Narumi et al. (2011) recently reported two patients with CH and high iodide uptake 
harboring biallelic TSHR mutations (R450H+T145I in one and R450H+I166fs in the other), 
supporting our previous findings. They termed this apparently discrepant phenotype 
nonclassic TSH resistance. 
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* At diagnosis; NA, not available; CH, congenital hypothyroidism, SCH, sub-clinical hypothyroidism; y, 
years; w, weeks; d, days; wt, wild type; US, ultrasonographic imaging 
Table 1. Summary of the TSHR loss-of-function mutations 
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4.4 Heterozygosity for loss-of-function mutations 
Heterozygous subjects carrying loss-of–function mutations in TSHR are commonly mildly 
affected, presenting with euthyroid hyperthyrotropinemia but with variable expressivity 
(Camilot et al., 2005; Sriphrapradang et al., 2011; Tenenbaum-Rakover et al., 2009). 
Heterozygotes are typically diagnosed with slightly increased TSH but normal free T4 (FT4) 
levels. At least one case of neonatal hypothyroidism has been reported as well (Camilot et 
al., 2005). In in-vitro models expressing the combination of wild-type and mutated TSHR, it 
has been shown that basal and TSH-stimulated cAMP production are reduced compared to 
cells transfected with wild-type receptor, albeit less severely than in biallelic mutations. 
These in-vitro studies are consistent with the dominant-negative effect of the mutated 
receptor on the activity of the wild type and explain the mild phenotype of the carriers 
(Calebiro et al., 2005; Tenenbaum-Rakover et al., 2009). The dominant-negative effect of the 
mutated receptor may result in reduction of cAMP accumulation, as well as reduced 
membrane cell-surface expression of the receptor and retention in intracellular 
compartments (Calebiro et al., 2005).  
5. Genotype-phenotype association 
The phenotype of the affected subjects correlates with the severity of the mutation, which 
is dependent on its location and type, and whether it is mono- or biallelic. Most of the 
described cases reveal a direct association between the severity of the mutation and the 
phenotype, which is reflected by the extent of increase in TSH and decrease in FT4 levels. 
The more severe mutations manifest in infancy with persistent CH, while the mild 
monoallelic mutations manifest as asymptomatic mild hyperthyrotropinemia. We 
identified 33 subjects carrying two novel TSHR gene mutations (P68S and L653V) in a 
large consanguineous kindred occurring as homozygous L653V (5 subjects), heterozygous 
P68S (4 subjects), heterozygous L653V (20 subjects), and compound heterozygous 
L653V/P68S (4 subjects). Our finding in a large cohort of affected members enabled us to 
assess the genotype-phenotype association. All homozygotes and compound 
heterozygotes presented with compensated RTSH, 9 out of 24 heterozygotes showed mild 
hyperthyrotropinemia and the others had normal TSH values. The clinical results were 
supported by in-vitro studies in which the L653V-mutated TSHR resulted in more severely 
impaired signal transduction than the other genotype combinations. However, large 
variability was found to exist between affected members. Among those with the 
homozygous L653V mutation, one child had CH and the other four, aged 3 to 20 years, 
had markedly elevated TSH, but FT4 levels were within the normal range; among the 
heterozygous members for the two different mutations, variable hyperthyrotropinemia 
was observed, with a few of the affected subjects showing normal thyroid function 
(Tenenbaum-Rakover et al., 2009). 
6. Outcome  
Despite several reports of patients affected with TSHR mutations, there are limited data 
on the long-term outcome of this condition. In subjects with TSHR mutations, it has been 
shown that TSH levels remain stable and they do not develop hypothyroidism; in 
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contrast, in autoimmune thyroid disease (AITD), overt hypothyroidism commonly 
develops over the years. In our abovementioned large cohort of affected family members, 
cross-sectional analysis showed neither a decrease nor an increase in TSH levels with age, 
suggesting stable compensated RTSH with an appropriately adjusted set point of 
pituitary-thyroid feedback (Tenenbaum-Rakover et al., 2009). In contrast to subclinical 
hypothyroidism in the context of AITD, the thyroidal compensation in mild to moderate 
RTSH is expected to be clinically stable with no progression toward true hypothyroidism 
or spontaneous regression toward normal TSH levels. Patients with homozygous or 
compound heterozygous mutations who are detected in infancy by neonatal screening to 
have CH may have normal FT4 levels despite elevated TSH levels after L-T4 withdrawal 
and in these patients, L-T4 replacement may not be needed. In contrast, development of 
overt hypothyroidism at the age of 15 years was shown in a patient homozygous for the 
R540H mutation who presented with compensated hypothyroidism in infancy (Mizuno et 
al., 2009), but not in an additional four subjects with the same genotype after long-term 
follow-up. Asymptomatic heterozygotes for TSHR mutations have normal or slightly 
elevated TSH levels with negative thyroid antibodies (Camilot et al., 2005). However, 
coexistence of thyroid autoantibodies has been reported in some cases of compensated 
RTSH, leading to overt hypothyroidism (Tonacchera et al., 2001). It is possible that 
carriers of TSHR mutations are at increased risk for AITD. TSHR is involved in AITD, 
TSH-stimulating autoantibodies in Graves’ disease and TSH-blocking antibodies in 
Hashimoto thyroiditis. Therefore, it has been speculated that modification of TSH 
structure by the mutated receptor may lead to AITD (Tonacchera et al., 2001). Fluctuation 
of TSH levels from slightly above normal to normal values have been observed in some 
cases by us and others (Tenenbaum-Rakover et al., 2009; Tonacchera et al., 2001). In view 
of the variability in outcome among affected individuals, careful long-term follow-up is 
recommended.  
7. Treatment 
The question of whether to treat patients with TSHR mutations with L-T4 is a matter of 
debate (Utiger, 1995). In cases with loss-of-function mutations in TSHR presenting with CH, 
early initiation of L-T4 therapy is recommended to prevent late-effect consequences of 
hypothyroidism as in other etiologies of CH. However, withdrawal of L-T4 at the age of 2 to 
3 years revealed transient hypothyroidism in some cases, putting the need for lifelong 
replacement therapy into question (Alberti et al., 2002; Tenenbaum-Rakover et al., 2009). 
Euthyroid hyperthyrotropinemia caused by TSHR mutations with mild to moderate loss of 
function maintains stable compensated RTSH and may not necessitate thyroid hormone 
replacement. Moreover, most patients with RTSH do not present with symptoms of 
hypothyroidism or with biochemical parameters of uncompensated hypothyroidism, such 
as elevated CPK and liver enzymes and hyperlipidemia (Tenenbaum-Rakover et al., 2009). 
The presence of normal FT4 levels argues against the need for replacement treatment, 
especially when inadvertent overtreatment, producing subclinical hyperthyroidism, can 
have undesirable effects (Samuels et al., 2008). In our long experience, no clinical benefit has 
been observed with L-T4 therapy. Contrasting with this approach, it has been shown that 
some subjects with RTSH have a slight decrease in FT4 levels compared to controls, although 
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remaining within the normal range, which may point to subclinical hypothyroidism in these 
affected patients. In addition, the possibility of secondary pituitary enlargement in patients 
with extreme hyperthyrotropinemia may support L-T4 replacement therapy. In view of the 
variability of phenotypes in different types of mutations, as well as between individuals 
with the same genotypes, it is recommended that careful follow-up and cautious 
administration of L-T4 be considered based on individual thyroid hormone levels in the 
clinical context. 
8. Differential diagnosis 
The diagnostic work-up of RTSH should exclude PAX8 mutations, which are characterized 
by thyroid dysgenesis associated with kidney abnormalities (Grüters et al., 2003; Park & 
Chatterjee, 2005), and mutations in guanine nucleotide binding subunit 1 (GNAS1), which 
encodes Gsα subunit and causes pseudohypoparathyroidism (PHP) type Ia. The latter 
inactivating mutations in Gsα lead to a syndrome of resistance to multiple hormones, 
including TSH (Mantovani et al., 2002). Another form of RTSH is an autosomal dominantly 
inherited disease characterized by euthyroid hyperthyrotropinemia, for which the specific 
gene has not yet been identified. This condition has been linked to a locus on chromosome 
15q25.3-26.1 (Grasberger et al., 2005(b)). In many of the cases with clinical characteristics of 
RTSH, no mutations have been found in TSHR, suggesting that additional genes are 
involved in RTSH syndrome (Xie et al., 1997). Bigenic defects in thyroid-synthesis pathways 
have been recently described. Coexistence of mutations in TPO (Sriphrapradang et al., 2011) 
and GNAS (Lado-Abeal et al., 2011), in addition to mutations in TSHR, has been reported in 
the same individuals. In those reports, the coexistence of  mutated TPO and TSHR in the 
same individuals belonging to the same kindred did not aggravate the severity of the RTSH 
phenotype (Sriphrapradang et al., 2011); similar observations were made for the presence of 
a monoallelic TSHR mutation coexisting with a GNAS mutation (Lado-Abeal et al., 2011). It 
is therefore suggested that in cases where TSHR mutations do not explain the phenotype, 
additional genes that are involved in thyroid hormone synthesis be screened. RTSH must be 
differentiated from AITD (Ross, 2000), the most common cause of subclinical 
hypothyroidism in the adult population. The presence of autoantibodies as well as a typical 
hypoechogenic pattern of the thyroid in ultasonographic imaging support the diagnosis of 
AITD. This is important from a clinical standpoint since in RTSH, hyperthyrotropinemia is 
almost always stable while in AITD, hypothyroidism develops with time in about 30% of 
the cases.  
9. Conclusion 
To date, about 50 different TSHR mutations have been reported presenting with a spectrum 
of phenotypes ranging from overt CH to mild euthyroid hyperthyrotropinemia. Subjects 
with euthyroid hyperthyrotropinemia commonly have stable TSH levels and do not develop 
overt hypothyroidism with time. The phenotype correlates with the genotype as the latter is 
reflected by the severity of hyperthyrotropinemia and the decrease in FT4 levels. Screening 
for TSHR mutations should be considered in individuals with apparent non-autoimmune 
subclinical hypothyroidism. In view of the variability in phenotypes and in outcome among 
individuals in this condition, careful long-term follow-up is recommended and replacement 
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therapy should be considered on an individual basis according to thyroid hormone levels in 
the clinical context. 
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thyroid ultrasonography and radioiodine therapy for hypothyroidism. "Hypothyroidism - Influences and
Treatments" contains many important specifications, results of scientific studies and innovations for endocrine
practice.
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